Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Regeneron Pharmaceuticals (NQ: REGN ) 980.16 +10.25 (+1.06%) Streaming Delayed Price Updated: 4:00 PM EDT, May 31, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Regeneron Pharmaceuticals < Previous 1 2 ... 25 26 27 28 29 30 31 32 Next > FDA Expands EUA for Lower Dose Subcutaneous Version of Regeneron's COVID-19 Antibody Cocktail June 04, 2021 The FDA has authorized a new, lower-dose version of Regeneron Pharmaceuticals Inc’s (NASDAQ: REGN) COVID-19 monoclonal antibody cocktail for those with... Via Benzinga Exposures COVID-19 Product Safety The Daily Biotech Pulse: Merck, AstraZeneca, Novartis Among Early Presenters At ASCO, Sanofi Strikes Breast Cancer Study Pact June 04, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 3) BioCryst Pharmaceuticals,... Via Benzinga Diversifying to Conquer: Fortress Biotech (FBIO) Partnering Expansion Driving Progress in Cancer Immunotherapy and Rare Disease Therapeutics June 03, 2021 The following article is sponsored by the clinical communications unit of Redington, Inc. The information contained in this article in no way represents investment advice or... Via Benzinga This Genetics Stock Could Have a Bright Future June 03, 2021 Here's one genetics play that you might want to put on your radar. Via The Motley Fool 2 Top Value Stocks to Hedge Against Inflation Woes June 03, 2021 Here are two stocks that can simultaneously add wealth to and protect your portfolio. Via The Motley Fool Topics Bonds Exposures Debt Markets Novartis Terminates Three Beovu Studies in Ocular Disorders Citing Patient Safety June 01, 2021 Novartis AG (NYSE: NVS) has announced that three Phase 3 studies evaluating Beovu (brolucizumab) in patients with retinal diseases will be terminated early after... Via Benzinga Regeneron Just Got a COVID-19 Boost May 29, 2021 It may be short lived. Via The Motley Fool Exposures COVID-19 The Surprising Move Vir Stock Made After Winning Covid Drug Authorization May 27, 2021 GlaxoSmithKline and Vir Biotechnology won Food and Drug Administration authorization for a Covid treatment on Wednesday, but Vir stock slipped Thursday. Via Investor's Business Daily Exposures COVID-19 3 Stocks to Build Your Portfolio Around May 26, 2021 These investments will help you diversify while giving you a good mix of dividends, growth, and stability. Via The Motley Fool Regeneron-Sanofi's Libtayo Scores CHMP's Positive Opinion For Two Advanced Cancer Settings May 24, 2021 The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted positive opinions for Regeneron Pharmaceuticals Inc (... Via Benzinga Facebook And Regeneron Lead The Nasdaq Lower Tuesday May 18, 2021 U.S. indices were trading lower Tuesday after U.S. Treasury Secretary Janet Yellen called for business leaders across the country to pay highe... Via Benzinga Sanofi-Regeneron Tout New Data For Dupixent From Pediatric Asthma Trial May 17, 2021 Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have unveiled detailed results from a Phase 3 trial evaluating Dupixent... Via Benzinga Cathie Wood Buys $26M Disney Shares And Sells $13M In Netflix: What You Need To Know May 16, 2021 Cathie Wood-led Ark Investment Management on Friday bought 150,556 shares, worth about $26.15 million, in Walt Disney Co (NYSE: DIS), marking its debut in the media and... Via Benzinga The QQQ Was Hammered Again Today. Here's Why. May 12, 2021 U.S. indices were trading lower across the board Wednesday after CPI data showed an increase in U.S. inflation, which has weighed on stocks. Via Benzinga Cathie Wood Sheds $33.6M Alibaba Shares On Earnings Day May 14, 2021 Cathie Wood-led Ark Investment Management on Thursday shed 162,840 shares, worth about $33.6 million, in Alibaba Group Holding (NYSE: BABA) after the company posted its first... Via Benzinga Tesla, Qualcomm Plummet, Lead QQQ Sharply Lower Monday May 10, 2021 The Nasdaq and companies in the broader technology sector were trading lower Monday amid profit-taking and overall weakness in the sector. Here&rsq... Via Benzinga Cathie Wood Piles Up Palantir For Third Day In A Row, Adding $39M Worth Of Shares May 12, 2021 Cathie Wood-led Ark Investment Management on Wednesday snapped up 2.07 million shares, worth about $39 million, in Palantir Technologies Inc (NYSE: PLTR), on a day the... Via Benzinga Review Of Present Therapies For Covid-19 May 09, 2021 A summary of authorized drugs for Covid-19, those in development, and those that have failed. Via Talk Markets Exposures COVID-19 ARKK Stocks Breakdowns and Bounces May 07, 2021 After struggling for most of the past couple of months, momentum and Tech stocks are broadly outperforming today. Via Talk Markets Cathie Wood Loads Up $57M In Palantir As Stock Stages Reversal On Q1 Earnings Beat May 12, 2021 Cathie Wood-led Ark Investment Management on Tuesday snapped up 2.8 million shares, worth about $56.7 million, in Palantir Technologies Inc (NYSE: PLTR) after the data analytics... Via Benzinga Return On Capital Employed Overview: Regeneron Pharmaceuticals May 07, 2021 Regeneron Pharmaceuticals (NASDAQ:REGN) posted a 4.65% decrease in earnings from Q4. Sales, however, increased by 4.37% over the previous quarter to $2.53 billion. Despite the... Via Benzinga Cathie Wood Cuts Apple Stake By 30% And Buys Coinbase, DraftKings May 10, 2021 Cathie Wood-led Ark Investment Management shed more shares of Apple Inc (NASDAQ: Via Benzinga Regeneron Pharmaceuticals Inc (REGN) Q1 2021 Earnings Call Transcript May 06, 2021 REGN earnings call for the period ending March 31, 2021. Via The Motley Fool Topics Earnings Exposures Financial Ocugen Shares Sink Despite OCU200 Being Comparable To Aflibercept In Reducing Neovascularization, Damage To Retina In Animal Study May 06, 2021 Ocugen Inc (NASDAQ: OCGN) has announced the presentation of new preclinical data evaluating the efficacy of OCU200 in in-vitro and in-vivo models for ocular... Via Benzinga Cathie Wood Slashes Apple Stake To Half — Also Trims Google, Fastly: What You Need To Know May 07, 2021 Cathie Wood-led Ark Investment Management nearly halved the Apple Inc (NASDAQ: AAPL) stake in the ARK Fintech Innovation ETF (NYSE: ARKF) on Thursday. ARKF shed 298,505 Apple... Via Benzinga Looking Into Regeneron Pharmaceuticals's Return On Capital Employed May 06, 2021 Looking Into Regeneron Pharmaceuticals's Return On Capital Employed Regeneron Pharmaceuticals (NASDAQ:REGN) posted a 4.65% decrease in earnings from Q4. Sales, however, increased... Via Benzinga Why Regeneron's Q1 Results Looked Great Despite Its Revenue Miss May 06, 2021 The big biotech delivered impressive revenue and earnings growth. Via The Motley Fool Regeneron Reports Mixed Bag On Q1 Earnings; Eylea Franchise Boosts Revenue May 06, 2021 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned $9.89 per share for the first quarter, beating the $9.03 estimate. Revenue of $2.53 billion narrowly missed... Via Benzinga Regeneron Pharmaceuticals: Q1 Earnings Insights May 06, 2021 Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) decreased 0.1% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 49.... Via Benzinga The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom May 06, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)... Via Benzinga Exposures Product Safety < Previous 1 2 ... 25 26 27 28 29 30 31 32 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.